$ALMS

Pangali Sanam sold $140K of ALMS

Pangali Sanam (Chief Legal Officer) sold 5,000 shares of ALUMIS INC. (ALMS) at $28.00 ($0.14M total) on 2026-07-06.

Original reporting
SEC EDGAR · Pangali Sanam
Published Jul 8, 2026, 8:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 8, 2026, 8:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALMS
Neutral
high confidence
Mentioned
$ALMS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALMSNeutralLow
01

Why it matters

The disclosure updates the record of insider activity. It may influence short-term sentiment, but it does not provide new operational or financial information about ALMS.

02

Market read

Traders may monitor insider activity, but this specific sale is unlikely to change valuation without accompanying company fundamentals.

03

What to watch

No 10b5-1 plan is stated, but the filing does not provide intent, liquidity needs, or whether other planned sales occurred.

Relevance 4/10Novelty 3/10Timing: Filed 2026-07-08 after-hours; reflects sale executed 2026-07-06.

Background

This is an SEC Form 4 insider transaction for ALUMIS INC. (ALMS) by its Chief Legal Officer.

Company-level read

Ticker impact

$ALMSNeutralHigh confidence
Context

SEC Form 4 shows ALMS Chief Legal Officer Pangali Sanam sold 5,000 shares at $28.00 on 2026-07-06 for $140,000.

Expected impact

Low likelihood of sustained price impact; any reaction is likely short-lived.

Evidence & confidence

The filing is a Form 4 insider transaction, not an earnings, guidance, or corporate event. The disclosed sale size is modest and does not indicate a company-specific catalyst.

Market effects

No clear sector read-across from a single insider sale.

None indicated.

None indicated.

Counterpoint

Insider sales can be tax or diversification-driven and may not reflect negative views, especially when holdings remain substantial.

Key entities

  • ALUMIS INC.

    Company whose insider transaction is disclosed on Form 4.

  • Pangali Sanam

    Chief Legal Officer who sold 5,000 shares at $28.00.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALMSMed

Why is Alumis stock rallying today?

Alumis (ALMS) stock rose 6.3% in pre-market trading after presenting long-term skin-clearance data for envudeucitinib at the Cantor Fitzgerald Global Healthcare Conference. Management highlighted potential partnerships and insider Srinivas Akkaraju bought 986,000 shares. The FDA application for envudeucitinib is expected in Q4 2026.

$ALMSMedAI 8/10

Alumis (ALMS) Plans to Advance Envudeucitinib After LUMUS Missed in the Overall Population

Alumis Inc. (ALMS) reported that its Phase 2b LUMUS trial of envudeucitinib in systemic lupus erythematosus did not meet primary or secondary endpoints in the overall population. However, a prespecified subgroup with high interferon gene signature showed numerically higher responses. The company plans to discuss Phase 3 trial design with regulators. Envudeucitinib was generally well tolerated.

$ALMSMedAI 8/10

Alumis Phase 2b LUMUS Trial Misses Endpoints; Stock Plunges

Alumis Inc. (ALMS) reported Phase 2b LUMUS trial results for Envudeucitinib in SLE, missing primary and secondary endpoints overall but showing promise in a subset of patients with high interferon gene signature. The drug demonstrated improvements in several measures in this subgroup and was well tolerated. The company plans to discuss Phase 3 development with regulators. ALMS stock fell over 55% in pre-market trading.